The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy

Laura Bonanno, Carlota Costa, Margarita Majem, Jose Javier Sanchez, Ana Gimenez-Capitan, Ignacio Rodriguez, Alain Vergnenegre, Bartomeu Massuti, Adolfo Favaretto, Massimo Rugge, Cinta Pallares, Miquel Taron, Rafael Rosell

Research output: Contribution to journalArticlepeer-review

Abstract

Platinum-based chemotherapy is the standard first-line treatment for non-oncogene- addicted non-small cell lung cancers (NSCLCs) and the analysis of multiple DNA repair genes could improve current models for predicting chemosensitivity. We investigated the potential predictive role of components of the 53BP1 pathway in conjunction with BRCA1. The mRNA expression of BRCA1, MDC1, CASPASE3, UBC13, RNF8, 53BP1, PIAS4, UBC9 and MMSET was analyzed by real-time PCR in 115 advanced NSCLC patients treated with first-line platinum-based chemotherapy. Patients expressing low levels of both BRCA1 and 53BP1 obtained a median progression-free survival of 10.3 months and overall survival of 19.3 months, while among those with low BRCA1 and high 53BP1 progression-free survival was 5.9 months (P

Original languageEnglish
Pages (from-to)1572-1581
Number of pages10
JournalOncotarget
Volume4
Issue number10
Publication statusPublished - Oct 2013

Keywords

  • 53BP1
  • BRCA1
  • DNA repair
  • Platinum
  • Predictive modeling

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy'. Together they form a unique fingerprint.

Cite this